A new home-made diffusive bag-type passive sampler called Lanwatsu was developed for benzene, toluene, ethylbenzene and xylene monitoring in roadside air. The passive samplers were outdoor validated and deployed together with two commercial passive samplers, Ultra I SKC Inc. and Radiello, for daily roadside air monitoring in East Asian cities including HoChiMinh, Hanoi, Cantho, Danang, Vungtau, Hue (Vietnam), Kuala Lumpur (Malaysia), Kyoto, Osaka (Japan), Nanjing (China) and Singapore in 2011. High daily benzene concentrations of 87, 52, 32, 23, 13, 12 and 48 µg/m³ were observed in HoChiMinh, Hanoi, Cantho, Danang, Hue, Vung Tau (Vietnam), and Kuala Lumpur (Malaysia), respectively. Kyoto and Osaka (Japan) were clean with daily benzene concentrations below 2.3 μg/m³. The daily benzene concentrations in Nanjing (China) and Singapore were 5.6 and 6.9 μg/m³, respectively. The three passive samplers were equivalent. Passive sampling by the Lanwatsu passive sampler is acceptable for daily outdoor benzene monitoring.
An international panel of movement disorders specialists explored the views and perceptions of people with Parkinson's disease (PD) about their condition and its treatment, including the potential mismatch between the clinician's view of the patient's condition and their own view of what aspects of the disease most affect their daily lives. The initiative was focused on Asian countries, so participants comprised experts in the management of PD from key centers in Asia, with additional insight provided by European and the North American movement disorders experts. Analysis of peer-reviewed publications on patient perceptions of PD and the factors that they consider important to their wellbeing identified several contributing factors to the mismatch of views, including gaps in knowledge of PD and its treatment, an understanding of the clinical heterogeneity of PD, and the importance of a multidisciplinary approach to patient care. The faculty proposed options to bridge these gaps to ensure that PD patients receive the personalized treatment they need to achieve the best possible outcomes. It was considered essential to improve patient knowledge about PD and its treatment, as well as increasing the awareness of clinicians of PD heterogeneity in presentation and treatment response. A multidisciplinary and shared-care approach to PD was needed alongside the use of patient-centered outcome measures in clinical trials and clinical practice to better capture the patient experience and improve the delivery of individualized therapy.